[184 Pages Report] The Patient-Derived Xenograft/PDX Model Market size was estimated at USD 326.36 million in 2023 and expected to reach USD 365.24 million in 2024, at a CAGR 12.27% to reach USD 734.07 million by 2030.
A Patient-Derived Xenograft (PDX) model is an advanced cancer research and drug development tool that directly transplants human tumor tissues or cells into immunodeficient or humanized mice, allowing for the growth and maintenance of the patient's tumor in a living organism. The increasing prevalence of cancer worldwide drives demand for effective therapies, leading to increased investment in research and development activities. However, ethical and regulatory concerns associated with acquiring patient tissue samples and discrepancies between human and mouse physiology restrain the growth of the patient-derived xenograft (PDX) mode. Furthermore, increasing government funding initiatives for cancer research and advancements in molecular characterization techniques are expected to create lucrative opportunities in the future.
The patient-derived xenograft/PDX model market in the Americas is highly evolving due to supportive government initiatives and the presence of various research institutes that contribute to advancements in this field. Moreover, biotechnology companies in the region are significant in providing PDX services for drug discovery and personalized medicine approaches. In the European Union, EU-funded projects focus on expanding access to PDX models across member countries. The Middle East is witnessing an increasing interest in PDX model research, with initiatives led by organizations and fostering expertise and resources for preclinical cancer model development. Asia-Pacific region’s investment in biomedical research has resulted in a surge of PDX model studies by domestic pharmaceutical companies. The government frameworks in the Asia-Pacific region also support initiatives that promote PDX model research, developing a potential platform for the patient-derived xenograft/PDX model market.
The market dynamics represent an ever-changing landscape of the Patient-Derived Xenograft/PDX Model Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.
- Market Drivers
- Growing demand for personalized medicine
- Oncology and preclinical development
- Government programs funding and services for applicants in the preparation of their preclinical programs and documentation
- Market Restraints
- High cost of personalized PDX model
- Market Opportunities
- Rising demand for humanized PDX Model
- Growth in pharma R&D
- Market Challenges
- Stringent guidelines regarding the ethical use of animals in cancer research
Type: Extensive use of mouse models in oncology to develop novel therapeutics
Mice models are the most widely used PDX models due to their properties such as small size, ease of handling, and genetic similarity to humans. These models contribute significantly to understanding tumor biology and developing novel therapeutic approaches in oncology. On the other hand, rat models have emerged as a valuable alternative to mice PDX models due to their larger size, which benefits surgical procedures, imaging, and sampling. Additionally, rats exhibit more diverse immune responses and higher fidelity in modeling certain human cancer types, such as glioma and sarcoma.
Tumor Type: Emphasis on gynecological tumor models to study gynecological cancers
Gastrointestinal (GI) tumor models are crucial to studying cancers that affect the digestive system, such as colorectal, gastric, and pancreatic cancer. These models aid in examining the underlying mechanisms of tumor development and metastasis and evaluating potential therapeutic options. Gynecological tumor models are essential for studying gynecological cancers, including ovarian, endometrial, and cervical cancer. Researchers employ hematological tumor models to study blood cancers, including leukemia, lymphoma, and multiple myeloma. Respiratory tumor models are vital for investigating lung cancer pathogenesis and treatment options. Urological tumor models, crucial for studying cancers of the urinary system such as bladder, kidney, and prostate cancer, aid researchers in comprehending disease development and identifying personalized treatment strategies.
Application: Increasing Patient-derived Xenograft (PDX) Model Adoption for basic cancer research
Patient-derived xenograft (PDX) models are highly valuable in basic cancer research as they closely mimic the tumor environment and patient heterogeneity. Biomarker analysis is essential for identifying predictive or prognostic markers that guide treatment decisions for individual patients. PDX models enable comprehensive biomarker development by capturing molecular changes during tumor growth and therapy response. Preclinical drug development relies heavily on PDX models to assess investigational therapies' safety, efficacy, and pharmacokinetic properties. They are a preferred choice for evaluating anticancer agents before entering clinical trials, as PDX models replicate the complexity and diversity of human cancers.
End-User: Rising applicability of patient-derived xenografts in academic and research institutes
Academic and research institutions primarily facilitate the study of cancer biology, drug efficacy testing, and personalized medicine development. These institutions use PDX models to identify novel therapeutic targets and understand tumor progression mechanisms. Contract Research Organizations (CROs) offer preclinical and clinical trial services for pharmaceutical and biotechnology companies using PDX models for drug discovery and development. CROs apply these models in various stages of drug development, including target identification/validation, lead optimization, pharmacokinetics/pharmacodynamics (PK/PD) studies, and toxicity evaluation. Pharmaceutical and biotechnology companies employ PDX models to support their drug discovery pipelines and address the demand for personalized oncology treatments.
The market disruption analysis delves into the core elements associated with market-influencing changes, including breakthrough technological advancements that introduce novel features, integration capabilities, regulatory shifts that could drive or restrain market growth, and the emergence of innovative market players challenging traditional paradigms. This analysis facilitates a competitive advantage by preparing players in the Patient-Derived Xenograft/PDX Model Market to pre-emptively adapt to these market-influencing changes, enhances risk management by early identification of threats, informs calculated investment decisions, and drives innovation toward areas with the highest demand in the Patient-Derived Xenograft/PDX Model Market.
The porter's five forces analysis offers a simple and powerful tool for understanding, identifying, and analyzing the position, situation, and power of the businesses in the Patient-Derived Xenograft/PDX Model Market. This model is helpful for companies to understand the strength of their current competitive position and the position they are considering repositioning into. With a clear understanding of where power lies, businesses can take advantage of a situation of strength, improve weaknesses, and avoid taking wrong steps. The tool identifies whether new products, services, or companies have the potential to be profitable. In addition, it can be very informative when used to understand the balance of power in exceptional use cases.
The value chain of the Patient-Derived Xenograft/PDX Model Market encompasses all intermediate value addition activities, including raw materials used, product inception, and final delivery, aiding in identifying competitive advantages and improvement areas. Critical path analysis of the <> market identifies task sequences crucial for timely project completion, aiding resource allocation and bottleneck identification. Value chain and critical path analysis methods optimize efficiency, improve quality, enhance competitiveness, and increase profitability. Value chain analysis targets production inefficiencies, and critical path analysis ensures project timeliness. These analyses facilitate businesses in making informed decisions, responding to market demands swiftly, and achieving sustainable growth by optimizing operations and maximizing resource utilization.
The pricing analysis comprehensively evaluates how a product or service is priced within the Patient-Derived Xenograft/PDX Model Market. This evaluation encompasses various factors that impact the price of a product, including production costs, competition, demand, customer value perception, and changing margins. An essential aspect of this analysis is understanding price elasticity, which measures how sensitive the market for a product is to its price change. It provides insight into competitive pricing strategies, enabling businesses to position their products advantageously in the Patient-Derived Xenograft/PDX Model Market.
The technology analysis involves evaluating the current and emerging technologies relevant to a specific industry or market. This analysis includes breakthrough trends across the value chain that directly define the future course of long-term profitability and overall advancement in the Patient-Derived Xenograft/PDX Model Market.
The patent analysis involves evaluating patent filing trends, assessing patent ownership, analyzing the legal status and compliance, and collecting competitive intelligence from patents within the Patient-Derived Xenograft/PDX Model Market and its parent industry. Analyzing the ownership of patents, assessing their legal status, and interpreting the patents to gather insights into competitors' technology strategies assist businesses in strategizing and optimizing product positioning and investment decisions.
The trade analysis of the Patient-Derived Xenograft/PDX Model Market explores the complex interplay of import and export activities, emphasizing the critical role played by key trading nations. This analysis identifies geographical discrepancies in trade flows, offering a deep insight into regional disparities to identify geographic areas suitable for market expansion. A detailed analysis of the regulatory landscape focuses on tariffs, taxes, and customs procedures that significantly determine international trade flows. This analysis is crucial for understanding the overarching legal framework that businesses must navigate.
The regulatory framework analysis for the Patient-Derived Xenograft/PDX Model Market is essential for ensuring legal compliance, managing risks, shaping business strategies, fostering innovation, protecting consumers, accessing markets, maintaining reputation, and managing stakeholder relations. Regulatory frameworks shape business strategies and expansion initiatives, guiding informed decision-making processes. Furthermore, this analysis uncovers avenues for innovation within existing regulations or by advocating for regulatory changes to foster innovation.
The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the Patient-Derived Xenograft/PDX Model Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).
The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the Patient-Derived Xenograft/PDX Model Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.
Invivo Biosystems and Bioreperia Partner to Enhance Cancer Drug Testing with Advanced PDX Models
InVivo Biosystems entered into a partnership with Bioreperia to enhance their capabilities in Patient-Derived Xenograft (PDX) models. This collaboration aims to utilize Bioreperia's expertise in zebrafish models to improve the preclinical evaluation of cancer therapies. By combining their technologies, the partnership seeks to accelerate drug development processes and provide more reliable data for predicting clinical outcomes, ultimately benefiting patients through more effective treatment options. [Published On: 2024-03-14]
Kiyatec and Xenostart Formally Announce a Collaborative Agreement to Help Reduce Drug Development Costs by Providing Correlative ex Vivo Efficacy Data Using Kiyatec’s 3D Spheroid Screening Platform, Kiya-Predict
Kiyatec and XenoSTART partnered to accelerate biopharmaceutical drug development through collaboration. Kiyatec's ex vivo 3D spheroid screening platform, combined with XenoSTART's Patient-Derived Xenograft (XPDX) models, aims to expedite the evaluation of therapeutic efficacy and in vivo outcomes using primary human tumors and tissues from XenoSTART's XPDX library. [Published On: 2023-06-29]
Soteria, Certis Partner to Generate Drug Response Predictions Using AI Platform, Mouse Xenografts
The Soteria Precision Medicine Foundation and Certis Oncology Solutions have joined forces to conduct a clinical study utilizing the CertisAI platform. This study aims to predict the response of patients with KRAS-mutated cancers to different drugs. To test the therapies, orthotopic patient-derived xenografts will be utilized, and the response will be monitored using a mouse-sized MRI instrument. [Published On: 2023-06-08]
The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the Patient-Derived Xenograft/PDX Model Market. This critical assessment involves a thorough analysis of the organization’s resources, capabilities, and overall performance to identify its core strengths and areas for improvement.
The report delves into recent significant developments in the Patient-Derived Xenograft/PDX Model Market, highlighting leading vendors and their innovative profiles. These include TheraIndx Lifesciences Pvt. Ltd., WuXi AppTec Co., Ltd., InSphero AG, GemPhamatech LLC, Creative Biolabs, EPO Berlin-Buch GmbH, LIDE Shanghai Biotech, Ltd., XENTECH TECHNOLOGIES PRIVATE LIMITED, Altogen Labs, Pharmatest Services LLC by ValiRx Finland Oy, BioDuro LLC, BioReperia AB, Inotiv, Inc. by Bioanalytical Systems, Inc., Urosphere SAS, Champions Oncology, Inc., Abnova Corporation, Crown Bioscience by JSR Corporation, Aragen Life Sciences Pvt. Ltd., Oncodesign Services, and Hera BioLabs Inc..
This research report categorizes the Patient-Derived Xenograft/PDX Model Market to forecast the revenues and analyze trends in each of the following sub-markets:
- Type
- Mice Models
- Rat Models
- Tumor Type
- Gastrointestinal Tumor Models
- Gynecological Tumor Models
- Hematological Tumor Models
- Respiratory Tumor Models
- Urological Tumor Models
- Application
- Basic Cancer Research
- Biomarker Analysis
- Preclinical Drug Development
- End-User
- Academic & Research Institutions
- Contract Research Organizations
- Pharmaceutical & Biotechnology Companies
- Region
- Americas
- Argentina
- Brazil
- Canada
- Mexico
- United States
- California
- Florida
- Illinois
- New York
- Ohio
- Pennsylvania
- Texas
- Asia-Pacific
- Australia
- China
- India
- Indonesia
- Japan
- Malaysia
- Philippines
- Singapore
- South Korea
- Taiwan
- Thailand
- Vietnam
- Europe, Middle East & Africa
- Denmark
- Egypt
- Finland
- France
- Germany
- Israel
- Italy
- Netherlands
- Nigeria
- Norway
- Poland
- Qatar
- Russia
- Saudi Arabia
- South Africa
- Spain
- Sweden
- Switzerland
- Turkey
- United Arab Emirates
- United Kingdom
- Americas
- Market Penetration: This section thoroughly overviews the current market landscape, incorporating detailed data from key industry players.
- Market Development: The report examines potential growth prospects in emerging markets and assesses expansion opportunities in mature segments.
- Market Diversification: This includes detailed information on recent product launches, untapped geographic regions, recent industry developments, and strategic investments.
- Competitive Assessment & Intelligence: An in-depth analysis of the competitive landscape is conducted, covering market share, strategic approaches, product range, certifications, regulatory approvals, patent analysis, technology developments, and advancements in the manufacturing capabilities of leading market players.
- Product Development & Innovation: This section offers insights into upcoming technologies, research and development efforts, and notable advancements in product innovation.
- What is the current market size and projected growth?
- Which products, segments, applications, and regions offer promising investment opportunities?
- What are the prevailing technology trends and regulatory frameworks?
- What is the market share and positioning of the leading vendors?
- What revenue sources and strategic opportunities do vendors in the market consider when deciding to enter or exit?
- Preface
- Research Methodology
- Executive Summary
- Market Overview
- Market Insights
- Patient-Derived Xenograft/PDX Model Market, by Type
- Patient-Derived Xenograft/PDX Model Market, by Tumor Type
- Patient-Derived Xenograft/PDX Model Market, by Application
- Patient-Derived Xenograft/PDX Model Market, by End-User
- Americas Patient-Derived Xenograft/PDX Model Market
- Asia-Pacific Patient-Derived Xenograft/PDX Model Market
- Europe, Middle East & Africa Patient-Derived Xenograft/PDX Model Market
- Competitive Landscape
- Competitive Portfolio
- List of Figures [Total: 24]
- List of Tables [Total: 378]
- List of Companies Mentioned [Total: 20]
What is a PDX Model?
PDX models are created by implanting human tumor cells in an immunodeficient mouse. These patients’ samples can be from various tissues of cancer patients, including breast cancer, colorectal cancer, and pancreatic cancer. PDX models preserve the genetic composition of the tumor, including the microenvironment, allowing more translationally relevant models to be developed. Researchers can then use these models to examine key tumor behaviors such as invasion, metastasis, and response and study the effectiveness of different therapies, including chemotherapy and radiation therapy.
Why Choose PDX models?
PDX models offer several advantages over other preclinical models, including the fact that the model has a natural tumor microenvironment, accurately reflecting the complex interaction between tumor cells and surrounding non-tumor elements such as connective tissues, vasculature, and immune cells. Another advantage of PDX models is their ability to preserve genetic diversity of heterogeneous tumors that are often present in cancer patients. This allows PDX models to better recapitulate clinical outcomes and responses to treatments. Also, drug screening with PDX models offers insight into drug efficacy, drug resistance development, and biomarker discovery.
PDX Models in Oncology:
PDX models hold immense promise in the field of oncology for drug discovery. Researchers can use PDX models to develop personalized cancer treatments by using samples taken from a specific patient’s tumors that can help predict the most viable drugs to use to treat that specific patient. PDX models can also help to discover potential cancer therapeutic targets by allowing researchers to study primary and metastatic patient samples. PDX models can enable researchers to develop more realistic cancer models for different subtypes of solid cancers and blood cancers or cancers that have a diverse range of mutations and treatment types.
The Use of PDX Models in Preclinical Development:
PDX models have gained popularity in drug development because they provide valuable insights about drugs, including their potency, efficacy, and toxicity. When using the PDX models for preclinical drug development, researchers can not only identify drug sensitivity and resistance but also the molecular markers and biological pathways targeted by drugs. The findings of the PDX models can efficiently assist drug developers in identifying biomarkers that can predict efficacy for cancer patients, toxicity, and mechanisms of resistance for drugs under development.
Without a doubt, the PDX model has revolutionized the field of preclinical cancer research and drug development. PDX models have immense potential in enabling the development of personalized cancer treatments, discovering potential cancer therapeutic targets, and offering valuable insights about drugs. PDX models provide cancer researchers with the much-needed precision and accuracy to develop better therapies for cancer patients. Therefore, the continued use and further development of the PDX model are critical to driving cancer research forward and developing better treatments for patients.
- How big is the Patient-Derived Xenograft/PDX Model Market?
- What is the Patient-Derived Xenograft/PDX Model Market growth?
- When do I get the report?
- In what format does this report get delivered to me?
- How long has 360iResearch been around?
- What if I have a question about your reports?
- Can I share this report with my team?
- Can I use your research in my presentation?